XNAS · Biotechnology
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$588.61+1.06%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
63/100
Positive
Score components
TickerWhale View
United Therapeutics scores 63 out of 100 overall, which we rate positive. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
Quality & growth
30%51Moderate
- Revenue growth 2.5%
- EPS growth 8.9%
Valuation
25%66Positive
- P/E 20.6
- EV/Sales 8.0
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
#383 by market cap in our coverage · ~1,400 employees · Listed 1999-06-17 · www.unither.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#33 / 139sector rank by TickerWhale Score
TickerWhale Score 63 vs sector average 54.6 (+8.4)
Revenue growth (industry)Top 76%
Gross margin (industry)Top 53%
Return on equity (industry)Top 14%
P/E (industry)Cheaper than 84%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
76/100Strong vs universe
Ranks 76th of 100 covered names on our technical composite — the composite itself scores 72/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
4 buy · 1 sell · 3 neutral of 8 votes
TickerWhale rates UTHR's technical setup strong — 76th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
8 / 9constructive
- vs 200-day+9.9%
- vs 50-day+9.6%
Momentum
Mixed
- RSI (14)58 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength24· trending
- MACD (12,26,9)sell(histogram -2.824)
How the classic verdict is reached
Moving averages (9) agree on buy — 8 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 1 sell · 3 neutral.
Result — 4 buy vs 1 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)20.6
- P/S (TTM)8.5
- P/B4.2
- EV/EBITDA—
- EV/Sales8.0
- PEG2.31
Profitability & returns
- Gross margin86.1%
- Net margin41.6%
- ROE21.3%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)2.5%
- EPS growth (YoY)8.9%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $27.0B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UTHRCurrentUnited Therapeutics | 63 | 72 | 20.6 | — | 4.2 | 8.0 | $588.61 | +1.06% | +2.5% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.